Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07298213 · ClinicalTrials.gov registry record · NA
Corazones Unidos Study
A NA study of MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease and CVD - Cardiovascular Disease, sponsored by University of Arizona.
- Recruiting
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT07298213: Recruiting NA study of MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease and CVD - Cardiovascular Disease, sponsored by University of Arizona.
NCT07298213 is a NA study of MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease and CVD - Cardiovascular Disease that is actively recruiting participants, run by University of Arizona. The registered enrollment target is 45 participants, below the 96-participant average among 5 other MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07298213, a NA study of MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease and CVD - Cardiovascular Disease, is actively recruiting participants, sponsored by University of Arizona.
- RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
CVD is the leading cause of death among individuals with MASLD, a risk factor for liver cancer. In Southern Arizona, CVD and cancer (including liver and gastric cancer) are among the leading causes of death for Mexican-origin adults.1 Given Mexican-origin adults' disproportionate burden of CVD-related mortality37 and higher rates of MASLD compared to other ethnic/racial groups; we urgently need to develop contextually tailored strategies for management of CVD risk factors and outcomes. Thus, the purpose of this study is to examine the acceptability and feasibility of a community health worker (CHW)-led intervention aimed to increase cardiovascular risk awareness and promote lifestyle modifications among Mexican-origin adults with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in the Southern Arizona region. The proposed project has the potential to improve health outcomes for this vulnerable population and contribute to the ACS-CHERC's overarching goal of improving health equity for Hispanic communities and family caregivers.
Primary Outcome
A composite score modeled after the American Heart Association Life's Essential Eight will be computed. Independent scores for diet, physical activity, nicotine exposure, sleep health, body mass index, blood lipids, blood glucose, and blood pressure will be calculated and then transformed into a graded score ranging from 0 (worst) to 100 (best).
Conditions Studied
Interventions
- BEHAVIORAL Your Heart, Your Health
Study Locations (1)
Arizona
- UA Collaboratory for Metabolic Disease Prevention & Treatment - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-07-18 |
| Est. Completion | 2026-07-17 |
| Phase | NA |
What NCT07298213 shows while recruiting
NCT07298213 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 96-participant average among 5 other MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease trials with a reported enrollment target (53% lower).
The record links to 2 conditions, with MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease appearing as the primary indexed condition, and to 1 intervention - of which Your Heart, Your Health is the first listed.
NCT07298213 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT07298213 about?
NCT07298213 is a clinical study titled "Corazones Unidos Study". CVD is the leading cause of death among individuals with MASLD, a risk factor for liver cancer. In Southern Arizona, CVD and cancer (including liver and gastric cancer) are among the leading causes of death for Mexican-origin adults.1 Given Mexican-origin adults' disproportionate burden of CVD-relat...
What is the current status of trial NCT07298213?
This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2025-07-18. Estimated completion is 2026-07-17.
What conditions does trial NCT07298213 study?
This clinical trial studies the following conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, CVD - Cardiovascular Disease.
What interventions are being tested in trial NCT07298213?
The interventions under investigation include: Your Heart, Your Health (BEHAVIORAL).
Who is sponsoring clinical trial NCT07298213?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07298213 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis
RECRUITING · NA
-
Food Insecurity and MASLD: A Fruit and Vegetable Intervention Study
RECRUITING · NA
-
Pediatric Metabolic Dysfunction-associated Steatotic Liver Disease and Food Insecurity
RECRUITING
-
Effect of Ketone Esters on Liver Fat Content and Metabolic Function
RECRUITING · Phase 2
-
Quantitative Ultrasound to Assess Steatotic Liver Disease in Children
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI